Stockscreener 앱 받기
3.295
1.93%
-0.065
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes - Stock Titan
Cadrenal Therapeutics CEO sells $22,422 in stock By Investing.com - Investing.com Australia
Cadrenal Therapeutics CEO sells $22,422 in stock - Investing.com
Form 4 Cadrenal Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
(CVKD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement - Stock Titan
Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down - RTTNews
Cadrenal raises $3M now, with $5.8M more possible from warrants - Stock Titan
Cadrenal Therapeutics raises $3 million in private placement - Investing.com
Cadrenal Therapeutics raises $3 million in private placement By Investing.com - Investing.com Australia
Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants - Quiver Quantitative
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Cadrenal Therapeutics Appoints Interim CFO John Sharp Under Master Services Agreement with Lohman & Associates - Minichart
Cadrenal Therapeutics Names Sharp Interim CFO - Moomoo
Cadrenal Therapeutics Board Member Steven Zelenkofske Resigns - Moomoo
Cadrenal Names Interim CFO, Realigns Board Structure - TipRanks
Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan
Cadrenal Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com - Investing.com South Africa
Price to earnings forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
Price to sales forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Cadrenal therapeutics CEO Pham sells $33,919 in stock - Investing.com
Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada
Cadrenal Therapeutics, Inc. Actuals & Estimates (NASDAQ:CVKD) - TradingView
CVKD Forecast — Price Target — Prediction for 2027 - TradingView
Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. By Investing.com - Investing.com South Africa
Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock. - Investing.com
Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia
Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades - Stock Titan
Cadrenal’s HIT drug data selected for presentation at Paris congress - Investing.com UK
Cadrenal’s HIT drug data selected for presentation at Paris congress By Investing.com - Investing.com South Africa
Cadrenal’s HIT drug gets late-breaking oral slot at ISTH 2026 - Stock Titan
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal CEO Pham sells $13,110 in company stock By Investing.com - Investing.com South Africa
Cadrenal CEO Pham sells $13,110 in company stock - Investing.com
Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust - Stock Titan
Cadrenal Therapeutics (CVKD) Pursues FDA Designation for Pediatric Treatment - GuruFocus
What date does Cadrenal Therapeutics, Inc.'s (CVKD) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Cadrenal plans rare pediatric disease designation for tecarfarin - Investing.com
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin - TipRanks
Cadrenal plans rare pediatric disease designation for tecarfarin By Investing.com - Investing.com South Africa
1.95%
2.70%
자본화:
|
볼륨(24시간):